Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
Novozymes Biopharma and Millipore Launch First Animal-Free Product from Strategic Alliance
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Novozymes Biopharma and Millipore Corporation have launched the first product from their alliance to supply animal-free cell culture supplements for bioprocessing. CellPrime™ rTransferrin AF is the first animal-free alternative to serum-derived human or bovine transferrin for industrial cell culture and upstream biopharmaceutical applications.
CellPrime™ is a range of animal-free cell culture supplements that enable customers to utilize defined, animal-free supplements in their biopharmaceutical production processes. The rTransferrin AF offers superior benefits over current plasma-derived alternatives, including facilitating effective iron uptake into cells for optimal cell culture and is now commercially available in scalable manufacturing quantities.
“We are pleased with the launch of our first commercial product and with the tremendous progress we have made in the first year of the alliance,” said Caspar Foghsgaard, Senior Manager, Novozymes Biopharma. “Both Novozymes and Millipore share a vision for providing biopharmaceutical manufacturers with a broad range animal-free supplements for industrial cell culture applications. The launch of animal-free transferrin for industrial scale production represents the first step toward that shared vision.”
CellPrime™ rTransferrin AF is designed to reduce regulatory concerns for biopharmaceutical manufacturers. It also improves the consistency of batch quality and productivity of customers’ industrial cell culture processes.
Manufactured in FDA-inspected facilities to cGMP standards, CellPrime™ rTransferrin AF is suitable for both research and commercial scale mammalian cell culture. Samples of the animal-free supplement are available from Millipore.
“The expansion of our animal-free cell culture supplements offering is a critical part of our Bioprocess Division’s long-term strategy,” said Andrew Bulpin, Vice President of Millipore’s Upstream Bioprocessing Business Unit. “By working with an industry leader like Novozymes, we can complement our applications expertise to bring new, innovative products to the market that improve productivity and reduce the risk to our customers.”
CellPrime™ is a range of animal-free cell culture supplements that enable customers to utilize defined, animal-free supplements in their biopharmaceutical production processes. The rTransferrin AF offers superior benefits over current plasma-derived alternatives, including facilitating effective iron uptake into cells for optimal cell culture and is now commercially available in scalable manufacturing quantities.
“We are pleased with the launch of our first commercial product and with the tremendous progress we have made in the first year of the alliance,” said Caspar Foghsgaard, Senior Manager, Novozymes Biopharma. “Both Novozymes and Millipore share a vision for providing biopharmaceutical manufacturers with a broad range animal-free supplements for industrial cell culture applications. The launch of animal-free transferrin for industrial scale production represents the first step toward that shared vision.”
CellPrime™ rTransferrin AF is designed to reduce regulatory concerns for biopharmaceutical manufacturers. It also improves the consistency of batch quality and productivity of customers’ industrial cell culture processes.
Manufactured in FDA-inspected facilities to cGMP standards, CellPrime™ rTransferrin AF is suitable for both research and commercial scale mammalian cell culture. Samples of the animal-free supplement are available from Millipore.
“The expansion of our animal-free cell culture supplements offering is a critical part of our Bioprocess Division’s long-term strategy,” said Andrew Bulpin, Vice President of Millipore’s Upstream Bioprocessing Business Unit. “By working with an industry leader like Novozymes, we can complement our applications expertise to bring new, innovative products to the market that improve productivity and reduce the risk to our customers.”
